JangoBio says human trials possible next year
post-template-default,single,single-post,postid-166416,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive

JangoBio says human trials possible next year


JangoBio says human trials possible next year

By Alex Moe

JangoBio, a biotech company developing a therapy to reduce the negative effects of aging, could be starting human trials as early as next year.

That’s according to company COO Bill Kohl, who spoke alongside CEO Craig Atwood at a recent progress update for interested parties at the Foley & Lardner law offices in Madison.

The company’s proposed method for reducing these effects, including the progression of age-related diseases, involves regrowing key cells in the body that are responsible for keeping hormones in balance. READ FULL STORY